JP2005513086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513086A5 JP2005513086A5 JP2003554125A JP2003554125A JP2005513086A5 JP 2005513086 A5 JP2005513086 A5 JP 2005513086A5 JP 2003554125 A JP2003554125 A JP 2003554125A JP 2003554125 A JP2003554125 A JP 2003554125A JP 2005513086 A5 JP2005513086 A5 JP 2005513086A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- lyophilized pharmaceutical
- composition
- composition further
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 15
- 239000013604 expression vector Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 101000821263 Homo sapiens Synapsin-3 Proteins 0.000 claims 3
- 101000859568 Methanobrevibacter smithii (strain ATCC 35061 / DSM 861 / OCM 144 / PS) Carbamoyl-phosphate synthase Proteins 0.000 claims 3
- 102100021920 Synapsin-3 Human genes 0.000 claims 3
- 239000007853 buffer solution Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108091029865 Exogenous DNA Proteins 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34232901P | 2001-12-20 | 2001-12-20 | |
| US60/342,329 | 2001-12-20 | ||
| PCT/US2002/041198 WO2003053365A2 (en) | 2001-12-20 | 2002-12-20 | Syn3 compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010022598A Division JP2010095549A (ja) | 2001-12-20 | 2010-02-03 | Ｓｙｎ３組成物およびその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513086A JP2005513086A (ja) | 2005-05-12 |
| JP2005513086A5 true JP2005513086A5 (enExample) | 2006-02-09 |
| JP4727923B2 JP4727923B2 (ja) | 2011-07-20 |
Family
ID=23341353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554125A Expired - Lifetime JP4727923B2 (ja) | 2001-12-20 | 2002-12-20 | Ｓｙｎ３組成物およびその方法 |
| JP2010022598A Withdrawn JP2010095549A (ja) | 2001-12-20 | 2010-02-03 | Ｓｙｎ３組成物およびその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010022598A Withdrawn JP2010095549A (ja) | 2001-12-20 | 2010-02-03 | Ｓｙｎ３組成物およびその方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20030170216A1 (enExample) |
| EP (1) | EP1456377B1 (enExample) |
| JP (2) | JP4727923B2 (enExample) |
| AU (1) | AU2002366809A1 (enExample) |
| CA (1) | CA2470999C (enExample) |
| CY (1) | CY1121982T1 (enExample) |
| DK (1) | DK1456377T3 (enExample) |
| ES (1) | ES2745068T3 (enExample) |
| MX (1) | MXPA04005942A (enExample) |
| PT (1) | PT1456377T (enExample) |
| SI (1) | SI1456377T1 (enExample) |
| TR (1) | TR201910060T4 (enExample) |
| WO (1) | WO2003053365A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
| US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
| US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
| US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
| CN101396555A (zh) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
| CA2548100C (en) * | 2003-12-10 | 2015-03-24 | Canji, Inc. | Methods and compositions for treatment of interferon-resistant tumors |
| MX369156B (es) | 2013-09-19 | 2019-10-30 | Janssen Vaccines & Prevention Bv | Formulaciones de adenovirus mejoradas. |
| EP3442588A4 (en) * | 2016-04-14 | 2020-02-19 | Trizell Ltd. | VIRAL VECTOR STABILIZATION |
| WO2025202543A1 (en) * | 2024-03-28 | 2025-10-02 | Rokote Laboratories Finland Oy | A vaccine composition comprising an adenoviral vector and an adenoviral vector delivery enhancing agent |
| WO2025238195A1 (en) * | 2024-05-16 | 2025-11-20 | Ferring International Center S.A. | Method for the purification of recombinant adenovirus vectors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105156B1 (en) | 1987-09-17 | 2006-09-12 | The Regents Of The University Of California | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| NZ240846A (en) * | 1990-12-06 | 1994-04-27 | Hoechst Ag | Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| US5795870A (en) | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
| ES2189808T3 (es) | 1993-10-15 | 2003-07-16 | Cytrx Corp | Composiciones de aporte terapeutico y metodos de uso de las mismas. |
| US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
| US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
| US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
| US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
| US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
| DE69732029T2 (de) * | 1996-04-26 | 2006-02-23 | Merck & Co., Inc. | Dna enthaltende impfstoffen |
| ES2210769T3 (es) * | 1997-06-13 | 2004-07-01 | Cydex Inc. | Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua. |
| DE19734860C2 (de) * | 1997-08-12 | 1999-12-16 | Bosch Gmbh Robert | Verfahren zur Bestimmung oxidierbarer Bestandteile in einem Gasgemisch |
| CN100471522C (zh) * | 1998-03-13 | 2009-03-25 | 惠氏 | 聚核苷酸组合物及其制备方法与用途 |
| US6166779A (en) * | 1999-04-27 | 2000-12-26 | Nucore Technology Inc. | Method for analog decimation of image signals |
| EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
| WO2004108898A2 (en) | 2003-06-04 | 2004-12-16 | Canji, Inc. | Transfection agents |
| CN101396555A (zh) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
| KR20060012661A (ko) * | 2003-06-04 | 2006-02-08 | 캔지, 인크. | 인터페론 요법을 위한 방법 및 조성물 |
| CA2548100C (en) * | 2003-12-10 | 2015-03-24 | Canji, Inc. | Methods and compositions for treatment of interferon-resistant tumors |
| JP2008203500A (ja) * | 2007-02-20 | 2008-09-04 | Fuji Xerox Co Ltd | ホログラム記録材料、ホログラム記録媒体、および、ホログラム記録方法 |
-
2002
- 2002-12-20 SI SI200231095T patent/SI1456377T1/sl unknown
- 2002-12-20 US US10/329,043 patent/US20030170216A1/en not_active Abandoned
- 2002-12-20 WO PCT/US2002/041198 patent/WO2003053365A2/en not_active Ceased
- 2002-12-20 CA CA2470999A patent/CA2470999C/en not_active Expired - Lifetime
- 2002-12-20 TR TR2019/10060T patent/TR201910060T4/tr unknown
- 2002-12-20 PT PT02805671T patent/PT1456377T/pt unknown
- 2002-12-20 MX MXPA04005942A patent/MXPA04005942A/es not_active Application Discontinuation
- 2002-12-20 EP EP02805671.1A patent/EP1456377B1/en not_active Expired - Lifetime
- 2002-12-20 JP JP2003554125A patent/JP4727923B2/ja not_active Expired - Lifetime
- 2002-12-20 ES ES02805671T patent/ES2745068T3/es not_active Expired - Lifetime
- 2002-12-20 DK DK02805671.1T patent/DK1456377T3/da active
- 2002-12-20 AU AU2002366809A patent/AU2002366809A1/en not_active Abandoned
-
2010
- 2010-02-03 JP JP2010022598A patent/JP2010095549A/ja not_active Withdrawn
- 2010-07-19 US US12/838,795 patent/US9115374B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 US US14/798,277 patent/US20150313926A1/en not_active Abandoned
-
2019
- 2019-09-03 CY CY20191100923T patent/CY1121982T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005513086A5 (enExample) | ||
| DE60006100D1 (de) | Lang wirkende insulinotrope peptide | |
| PE20071063A1 (es) | Formulaciones de proteinas estables | |
| ECSP024397A (es) | Combinaciones de inihibidores de dipeptildil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus | |
| AU6076299A (en) | Freeze-dried hepatitis a attenuated live vaccine and its stabilizer | |
| NL300281I2 (nl) | Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| JP2002532432A5 (enExample) | ||
| DE69740096D1 (de) | Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid | |
| JP2001522783A5 (enExample) | ||
| NO940663L (no) | Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin | |
| EP1593379A3 (en) | Uses of PPAR-gamma agonists in neutrophil-induced diseases | |
| UY26330A1 (es) | " método para mejorar la piel y el pelaje de mascotas". | |
| JP2003505345A5 (enExample) | ||
| CO5280094A1 (es) | Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo | |
| NZ596367A (en) | Lyophilized therapeutic peptibody formulations | |
| NO20012716L (no) | Terapeutisk middel for undertrykkelse av snorkelyder | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| CA2144514A1 (en) | Morphogen-induced liver regeneration | |
| AR004341A1 (es) | Vacunas contra tumores y procedimiento para su produccion. | |
| DK1774846T3 (da) | Rotorrive | |
| JP2005520779A5 (enExample) | ||
| JP2008510716A5 (enExample) | ||
| NZ506631A (en) | Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization | |
| WO2004030650A3 (de) | Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung | |
| WO2001070290A3 (en) | Injectable microspheres for tissue construction |